Physician profile
Robert L Elder
NPI 1154353787
$19,308.78
in general payments reported to CMS, 2019-2025
62 companies · $750 in 2025
The $750 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,727 · 2020: $2,837 · 2021: $3,660 · 2022: $2,792 · 2023: $3,163 · 2024: $3,379 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,178 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,178.32 |
| Education | $114.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,358.25 | 2021-2025 | |
| Novo Nordisk INC | $1,537.21 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,399.67 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $1,178.18 | 2019-2025 | Airsupra, Farxiga, Flumist Quadrivalent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,004.52 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $907.01 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $894.56 | 2019-2024 | Linzess |
| Glaxosmithkline, LLC. | $787.22 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $776.31 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $704.26 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $661.35 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Teva Pharmaceuticals USA, INC. | $604.67 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $543.78 | 2021-2024 | Qelbree, Tlando, Xyosted |
| Allergan, INC. | $537.63 | 2019-2020 | |
| Astellas Pharma US INC | $470.88 | 2019-2024 | Veozah, Myrbetriq |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Elder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.